AstraZeneca PLC (AZN)vsQuipt Home Medical Corp (QIPT)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
QIPT
Quipt Home Medical Corp
$3.65
0.00%
HEALTHCARE · Cap: $162.30M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 22068% more annual revenue ($58.74B vs $264.97M). AZN leads profitability with a 17.4% profit margin vs -4.0%. AZN earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
QIPT
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Intrinsic value data unavailable for QIPT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Revenue surging 32.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 1.5%
ROE of -9.3% — below average capital efficiency
Earnings declined 97.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : QIPT
The strongest argument for QIPT centers on Revenue Growth, Price/Book. Revenue growth of 32.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : QIPT
The primary concerns for QIPT are Market Cap, Operating Margin, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while QIPT is a hypergrowth play — different risk/reward profiles.
QIPT carries more volatility with a beta of 0.49 — expect wider price swings.
QIPT is growing revenue faster at 32.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (66/100 vs 40/100), backed by strong 17.4% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Quipt Home Medical Corp
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?